Exploration in the Mechanism of Ginsenoside Rg5 for the Treatment of Osteosarcoma by Network Pharmacology and Molecular Docking

Abstract

Objective:: Osteosarcoma is a primary malignancy originating from mesenchymal tissue characterized by rapid growth, early metastasis and poor prognosis. Ginsenoside Rg5 (G-Rg5) is a minor ginsenoside extracted from Panax ginseng C.A. Meyer which has been discovered to possess anti-tumor properties. The objective of current study was to explore the mechanism of G-Rg5 in the treatment of osteosarcoma by network pharmacology and molecular docking technology.

Methods:: Pharmmapper, SwissTargetPrediction and similarity ensemble approach databases were used to obtain the pharmacological targets of G-Rg5. Related genes of osteosarcoma were searched for in the GeneCards, OMIM and DrugBank databases. The targets of G-Rg5 and the related genes of osteosarcoma were intersected to obtain the potential target genes of G-Rg5 in the treatment of osteosarccoma. The STRING database and Cytoscape 3.8.2 software were used to construct the protein–protein interaction (PPI) network, and the Database for Annotation, Visualization and Integrated Discovery (DAVID) platform was used to perform gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. AutoDock vina software was used to perform molecular docking between G-Rg5 and hub targets. The hub genes were imported into the Kaplan–Meier Plotter online database for survival analysis.

Results:: A total of 61 overlapping targets were obtained. The related signaling pathways mainly included PI3K-Akt signaling pathway, Proteoglycans in cancer, Lipid and atherosclerosis and Kaposi sarcoma-associated herpesvirus infection. Six hub targets including PIK3CA, SRC, TP53, MAPK1, EGFR, and VEGFA were obtained through PPI network and targets-pathways network analyses. The results of molecular docking showed that the binding energies were all less than –7 kcal/mol. And the results of survival analysis showed TP53 and VEGFA affect the prognosis of sarcoma patients.

Conclusion:: This study explored the possible mechanism of G-Rg5 in the treatment of osteosarcoma using network pharmacology method, suggesting that G-Rg5 has the characteristics of multi-targets and multi-pathways in the treatment of osteosarcoma, which lays a foundation for the follow-up experimental and clinical researches on the therapeutic effects of G-Rg5 on osteosarcoma.

Keywords

Ginsenoside Rg5 / Molecular docking / Network pharmacology / Osteosarcoma / Survival analysis

References

[1] Chang X, Ma Z, Zhu G, Lu Y, Yang J. New perspective into mesenchymal stem cells: molecular mechanisms regulating osteosarcoma. J Bone Oncol. 2021;29:100372.

[2] Xu G, Wu H, Zhang Y, Xu Y, Guo X, Baklaushev VP, et al. Risk and prognostic factors for different organ metastasis in primary osteosarcoma: a large population-based analysis. Orthopaedic Surg. 2022;14(4):714–719.

[3] Chen R, Guan Z, Zhong X, Zhang W, Zhang Y. Network pharmacology prediction: the possible mechanisms of Cinobufotalin against osteosarcoma. Comput Math Methods Med. 2022;2022(3197402):1–9.

[4] Harrison DJ, Geller DS, Gill JD, Lewis VO, Gorlick R. Current and future therapeutic approaches for osteosarcoma. Expert Review of Anticancer Therapy. 2018;18(1):39–50.

[5] Ando K, Heymann MF, Stresing V, Mori K, Rédini F, Heymann D. Current therapeutic strategies and novel approaches in osteosarcoma. Cancers. 2013;5(2):591–616.

[6] Liu MY, Zhang L, Zang WD, Zhang KG, Li HJ, Gao YZ. Pharmacological effects of resveratrol in intervertebral disc degeneration: a literature review. Orthopaedic Surgery. 2022;14(12):3141–3149.

[7] Liu MY, Liu F, Gao YL, Yin JN, Yan WQ, Liu JG, et al. Pharmacological activities of ginsenoside Rg5 (review). Experimental and Therapeutic Medicine. 2021;22(2):840.

[8] Liu MY, Li HJ, Yang C, Zang WD, Liu ZD, Zhang L, et al. Insight into the pharmacological effects of andrographolide in musculoskeletal disorders. Biomed Pharmacother = Biomed Pharmacother. 2022;146:112583.

[9] Kim S, Kim N, Jeong J, Lee S, Kim W, Ko S-G, et al. Anti-cancer effect of panax ginseng and its metabolites: from traditional medicine to modern drug discovery. Processes. 2021;9(8):1344.

[10] Jegal J, Jeong EJ, Yang MH. A review of the different methods applied in ginsenoside extraction from Panax ginseng and Panax quinquefolius roots. Nat Prod Commun. 2019;14(9):1–10.

[11] Liu MY, Liu F, Li YJ, Yin JN, Gao YL, Wang XY, et al. Ginsenoside Rg5 inhibits human osteosarcoma cell proliferation and induces cell apoptosis through PI3K/Akt/mTORC1-related LC3 autophagy pathway. Oxid Med Cell Longevity. 2021;2021(5040326):1–12.

[12] Wu C, Zheng W, Zhang J, He X. Exploring the mechanism of curcumin on retinoblastoma based on network pharmacology and molecular docking. Evid Based Complement Alternat Med. 2022;2022(2407462):1–8.

[13] Zhang J, Fan F, Liu A, Zhang C, Li Q, Zhang C, et al. Icariin: a potential molecule for treatment of knee osteoarthritis. Front Pharmacol. 2022;13:811808.

[14] Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, et al. STRING v9.1: protein–protein interaction networks, with increased coverage and integration. Nucl Acids Res. 2013;41(Database issue):D808-15.

[15] Cai D, Ma X, Guo H, Zhang H, Bian A, Yu H, et al. Prognostic value of p16, p53, and pcna in sarcoma and an evaluation of immune infiltration. Journal of Orthopaedic Surgery and Research. 2022;17(1):305.

[16] Zhang J, Yu XH, Yan YG, Wang C, Wang WJ. PI3K/Akt signaling in osteosarcoma. Clin Chim Acta; Int J Clin Chem. 2015;444:182–192.

[17] Li Y, Lu J, Bai F, Xiao Y, Guo Y, Dong Z. Ginsenoside Rg3 suppresses proliferation and induces apoptosis in human osteosarcoma. Biomed Res Int. 2018;2018(4306579):1–9.

[18] Cui J, Dean D, Hornicek FJ, Chen Z, Duan Z. The role of extracelluar matrix in osteosarcoma progression and metastasis. J Exp Clin Cancer Res: CR. 2020;39(1):178.

[19] Leblanc R, Sahay D, Houssin A, Machuca-Gayet I, Peyruchaud O. Autotaxin-β interaction with the cell surface via syndecan-4 impacts on cancer cell proliferation and metastasis. Oncotarget. 2018;9(69):33170–33185.

[20] Chen Q, Chen J, Li Y, Liu D, Zeng Y, Tian Z, et al. Kaposi's sarcoma herpesvirus is associated with osteosarcoma in Xinjiang populations. Proc Nat Acad Sci U S A. 2021;118(10):1–8.

[21] He ML, Wu Y, Zhao JM, Wang Z, Chen YB. PIK3CA and AKT gene polymorphisms in susceptibility to osteosarcoma in a Chinese population. Asian Pac J Cancer Prevent: APJCP. 2013;14(9):5117–5122.

[22] Qu L, Li G, Xia D, Hongdu B, Xu C, Lin X, et al. PRKCI negatively regulates autophagy via PIK3CA/AKT–MTOR signaling. Biochem Biophys Res Commun. 2016;470(2):306–312.

[23] Eng L, Azad AK, Habbous S, Pang V, Xu W, Maitland-van der Zee AH, et al. Vascular endothelial growth factor pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a systematic review and meta-analysis. Clin Cancer Res. 2012;18(17):4526–4537.

[24] Zhang C, Wang L, Xiong C, Zhao R, Liang H, Luo X. The role of vascular endothelial growth factor as a prognostic and clinicopathological marker in osteosarcoma: a systematic review and meta-analysis. J Orthop Surg Res. 2021;16(1):738.

[25] Vimalraj S, Saravanan S, Raghunandhakumar S, Anuradha D. Melatonin regulates tumor angiogenesis via miR-424-5p/VEGFA signaling pathway in osteosarcoma. Life Sci. 2020;256:118011.

[26] Zhang L, Lv Z, Xu J, Chen C, Ge Q, Li P, et al. MicroRNA-134 inhibits osteosarcoma angiogenesis and proliferation by targeting the VEGFA/VEGFR1 pathway. FEBS J. 2018;285(7):1359–1371.

[27] Synoradzki KJ, Bartnik E, Czarnecka AM, Fiedorowicz M, Firlej W, Brodziak A, et al. TP53 in biology and treatment of osteosarcoma. Cancers. 2021;13(17):1–23.

[28] Ando T, Kudo Y, Iizuka S, Tsunematsu T, Umehara H, Shrestha M, et al. Ameloblastin induces tumor suppressive phenotype and enhances chemosensitivity to doxorubicin via Src-Stat3 inactivation in osteosarcoma. Sci Rep. 2017;7:40187.

[29] Wang X, Zhao X, Yi Z, Ma B, Wang H, Pu Y, et al. WNT5A promotes migration and invasion of human osteosarcoma cells via SRC/ERK/MMP-14 pathway. Cell Biol Int. 2018;42(5):598–607.

[30] Luo Y, Gao X, Zou L, Lei M, Feng J, Hu Z. Bavachin induces ferroptosis through the STAT3/P53/SLC7A11 Axis in osteosarcoma cells. Oxid Med Cell Longevity. 2021;2021(1783485):1–14.

[31] Wu J, Zhang C, Chen L. MiR-511 mimic transfection inhibits the proliferation, invasion of osteosarcoma cells and reduces metastatic osteosarcoma tumor burden in nude mice via targeting MAPK1. Cancer Biomarkers: Section A Disease Markers. 2019;26(3):343–351.

RIGHTS & PERMISSIONS

2023 2023 The Authors. Orthopaedic Surgery published by Tianjin Hospital and John Wiley & Sons Australia, Ltd.